Indications

KANJINTI™ is a prescription medicine used for the treatment of:

  • Adjuvant breast cancer
    • KANJINTI™ is used for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and that has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high-risk feature. High risk is defined as ER/PR-positive with one of the following features: tumor size > 2 cm, age < 35 years, or tumor grade 2 or 3. ... Read More 
    • KANJINTI™ can be used in different ways:
      • As part of a treatment course including the chemotherapy drugs doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. This treatment course is known as "AC → TH"
      • With the chemotherapy drugs docetaxel and carboplatin. This treatment course is known as "TCH"
      • Alone after treatment with multiple other therapies, including an anthracycline (doxorubicin) based therapy (a type of chemotherapy)
    • Patients are selected for therapy based on an FDA-approved test for trastuzumab.
  • Metastatic Breast Cancer
    • KANJINTI™ has 2 approved uses in metastatic breast cancer:
      • KANJINTI™ in combination with the chemotherapy drug paclitaxel is approved for the first line treatment of Human Epidermal growth factor Receptor 2-positive (HER2+) metastatic breast cancer
      • KANJINTI™ alone is approved for the treatment of HER2-positive breast cancer in patients who have received one or more chemotherapy courses for metastatic disease
    • Patients are selected for therapy based on an FDA-approved test for trastuzumab.
Asset 1

There is treatment for your HER2 positive (HER2+) breast OR GASTRIC cancer—and it is called KANJINTI™1

KANJINTI™ IS:

  • Approved by the FDA (Food and Drug Administration) for HER2+ breast and gastric cancer. KANJINTI™ is also known by its chemical name, trastuzumab-anns (trast-OO-zoo-mab).1
  • A biologic, which is a drug made from a living cell. Biologic medicines are used to treat many conditions.1,2

KANJINTI™ WORKS WITH YOUR BODY'S IMMUNE SYSTEM TO HELP FIGHT CANCER CELLS3

kanjinti attaches to her2 receptors on cells
KANJINTI™ attaches to HER2 receptors on cells.3
this prevents cancer cells from growing and multiplying
THIS PREVENTS cancer cells from growing and multiplying.3,*

* Because normal cells have HER2 receptors, KANJINTI™ can also prevent their growth and cause serious side effects.

the cancer cell is then destroyed by the body's defenses
the cancer cell is then destroyed by the body's defenses.3
How does KANJINTI™ work?
NORMAL CELL

Normal cells have some HER2 receptors.4

How does KANJINTI™ work?
HER2+ CANCER CELL

HER2+ cancer cells have many more
HER2 receptors than normal cells.4

How does KANJINTI™ work?
HER2+ CANCER CELL

Why KANJINTI™?

Proven TO BE AS EFFECTIVE AS HERCEPTIN®

KANJINTI™ is a biosimilar to the cancer drug Herceptin® and is FDA-approved for the same uses. KANJINTI™ has been tested worldwide and has been proven to have similar side effects as Herceptin®.1,5

Single transition

CAN I BE GIVEN KANJINTI™ IF I'VE ALREADY STARTED WITH HERCEPTIN®?

Single transition

KANJINTI™ has been proven to be as effective as Herceptin® in a study. Some patients in this study started treatment with Herceptin®, then were transitioned to KANJINTI™ for the rest of the study to make sure the side effects were similar.5

Proven similar to Herceptin
Clinically studied with patients worldwide

A few things to keep in mind as you start KANJINTI™

Now that you know more about HER2+ breast and gastric cancer and KANJINTI™, you may have some questions about starting this course of therapy.

How is KANJINTI™ Prescribed?
KANJINTI™ may be prescribed alone
or with chemotherapy.1

Your doctor may choose to use KANJINTI™ with or without chemotherapy. Your doctor or nurse will discuss which combination of treatments is right for you.

KANJINTI™ Infusion
Kanjinti™ is given through an infusion.1

You will receive KANJINTI™ either once a week or once every 3 weeks for as long as your doctor thinks it is working for you and as long as you are not having any serious side effects.3

The points above offer only an outline of what you might expect when starting KANJINTI™. Your doctor will make these treatment decisions with you. If your treatment plan is not clear, please talk with your treatment team.


REGULAR HEART MONITORING IS IMPORTANT1

Per standard treatment with KANJINTI™, and similar drugs like Herceptin®, you will receive regular heart function checkups. These checkups occur throughout the course of your treatment.1 Heart function will be tested with an ECHO or MUGA scan1. An ECHO scan is an ultrasound image of the heart. A MUGA scan takes a moving picture of your heart pumping blood.6

KANJINTI™ and Heart Monitoring
KANJINTI™ and Heart Monitoring

ECHO = echocardiogram; HER2 = human epidermal growth factor receptor 2; MUGA = multigated blood-pool imaging.


What to look out for

You should tell your doctor or nurse as soon as possible if you feel unwell or develop the following:1

  • Breathlessness and cough
  • Swelling in your ankles/legs or face
  • Feeling your heart flutter or an irregular heartbeat
  • Weight gain of more than 5 pounds in 24 hours
  • Dizziness or loss of consciousness
  • Be sure to review the Important Safety Information to learn more about potential side effects and symptoms you need to watch for to help your doctor know when you are having a side effect

Important Safety Information

What are the possible Serious Side Effects with KANJINTI™?

KANJINTI™ is not for everyone. Be sure to contact your doctor if you are experiencing any of the following potentially life threatening side effects:

HEART PROBLEMS
  • These include congestive heart failure or reduced heart function—with or without symptoms. The risk for and seriousness of these heart problems were highest in people who received both a trastuzumab product, like KANJINTI™, and a certain type of chemotherapy (anthracycline). In a study of adjuvant (early) breast cancer, one patient died of significantly weakened heart muscle. Your doctor will check for signs of heart problems before, during, and after treatment with KANJINTI™.
INFUSION REACTIONS, including:
  • Fever and chills
  • Feeling sick to your stomach (nausea)
  • Throwing up (vomiting)
  • Pain (in some cases at tumor sites)
  • Headache
  • Dizziness
  • Shortness of breath

These signs usually happen within 24 hours after receiving KANJINTI™.

Tell your doctor if you:
  • Are a woman who could become pregnant, or may be pregnant.
    • KANJINTI™ may result in the death of an unborn baby or birth defects.
    • Contraception should be used while receiving KANJINTI™ and for seven months after your last dose of KANJINTI™.
    • Tell your doctor right away if you are exposed to KANJINTI™ during pregnancy or within 7 months of becoming pregnant.
  • Have any signs of SEVERE LUNG PROBLEMS, including:
    • Severe shortness of breath
    • Fluid in or around the lungs
    • Weakening of the valve between the heart and the lungs
    • Not enough oxygen in the body
    • Swelling of the lungs
    • Scarring of the lungs
    • Your doctor may check for signs of severe lung problems
  • Have LOW WHITE BLOOD CELL COUNTS
    • Low white blood cell counts can be life threatening.
    • Low white blood cell counts were seen more often in patients receiving trastuzumab plus chemotherapy than in patients receiving chemotherapy alone.
    • Your doctor may test your blood and check for signs of low white blood cell counts.
What are the possible more common side effects of KANJINTI™?
Side Effects Seen most often with KANJINTI™
  • Some patients receiving trastuzumab products, like KANJINTI™, for breast cancer had the following side effects:
    • Fever
    • Feeling sick to your stomach (nausea)
    • Throwing up (vomiting)
    • Infusion reactions
    • Diarrhea
    • Infections
    • Increased cough
    • Headache
    • Feeling tired
    • Shortness of breath
    • Rash
    • Low white and red blood cell counts
    • Muscle pain
  • Some patients receiving trastuzumab products, like KANJINTI™, for metastatic stomach cancer had the following side effects:
    • Low white blood cell counts
    • Diarrhea
    • Feeling tired
    • Low red blood cell counts
    • Swelling of the mouth lining
    • Weight loss
    • Upper respiratory tract infections
    • Fever
    • Low platelet counts
    • Swelling of the mucous membranes
    • Swelling of the nose and throat
    • Change in taste

These are not all the possible side effects of KANJINTI™. For more information, ask your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.


Indications

KANJINTI™ is a prescription medicine used for the treatment of:

  • Adjuvant breast cancer
    • KANJINTI™ is used for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and that has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high-risk feature. High risk is defined as ER/PR-positive with one of the following features: tumor size > 2 cm, age < 35 years, or tumor grade 2 or 3.
    • KANJINTI™ can be used in different ways:
      • As part of a treatment course including the chemotherapy drugs doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. This treatment course is known as "AC → TH"
      • With the chemotherapy drugs docetaxel and carboplatin. This treatment course is known as "TCH"
      • Alone after treatment with multiple other therapies, including an anthracycline (doxorubicin) based therapy (a type of chemotherapy)
    • Patients are selected for therapy based on an FDA-approved test for trastuzumab.
  • Metastatic Breast Cancer
    • KANJINTI™ has 2 approved uses in metastatic breast cancer:
      • KANJINTI™ in combination with the chemotherapy drug paclitaxel is approved for the first line treatment of Human Epidermal growth factor Receptor 2-positive (HER2+) metastatic breast cancer
      • KANJINTI™ alone is approved for the treatment of HER2-positive breast cancer in patients who have received one or more chemotherapy courses for metastatic disease
    • Patients are selected for therapy based on an FDA-approved test for trastuzumab.
  • Gastric Cancer
    • KANJINTI™ is approved, in combination with chemotherapy (cisplatin and either capecitabine or 5-fluorouracil), for the treatment of HER2-positive metastatic cancer of the stomach or gastroesophageal junction (where the esophagus meets the stomach) in patients who have not received prior treatment for their metastatic disease.
    • Patients are selected for therapy based on an FDA-approved test for trastuzumab.

Please see full Prescribing Information, including Boxed WARNINGS.

Herceptin® (trastuzumab) is a registered trademark of Genentech USA, Inc.